127 related articles for article (PubMed ID: 38341081)
1. Inhibition of RhoGEF/RhoA alleviates regorafenib resistance and cancer stemness via Hippo signaling pathway in hepatocellular carcinoma.
Zhou HM; Chen DH; Diao WJ; Wu YF; Zhang JG; Zhong L; Jiang ZY; Zhang X; Liu GL; Li Q
Exp Cell Res; 2024 Mar; 436(1):113956. PubMed ID: 38341081
[TBL] [Abstract][Full Text] [Related]
2. Changes in Wnt and TGF-β Signaling Mediate the Development of Regorafenib Resistance in Hepatocellular Carcinoma Cell Line HuH7.
Karabicici M; Azbazdar Y; Ozhan G; Senturk S; Firtina Karagonlar Z; Erdal E
Front Cell Dev Biol; 2021; 9():639779. PubMed ID: 34458250
[TBL] [Abstract][Full Text] [Related]
3. RAB27A-dependent release of exosomes by liver cancer stem cells induces Nanog expression in their differentiated progenies and confers regorafenib resistance.
Huang H; Hou J; Liu K; Liu Q; Shen L; Liu B; Lu Q; Zhang N; Che L; Li J; Jiang S; Wang B; Wen Q; Hu L; Gao J
J Gastroenterol Hepatol; 2021 Dec; 36(12):3429-3437. PubMed ID: 34258777
[TBL] [Abstract][Full Text] [Related]
4. CRISPR Loss-of-Function Screen Identifies the Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma.
Suemura S; Kodama T; Myojin Y; Yamada R; Shigekawa M; Hikita H; Sakamori R; Tatsumi T; Takehara T
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31540262
[TBL] [Abstract][Full Text] [Related]
5. Collagen I-DDR1 signaling promotes hepatocellular carcinoma cell stemness via Hippo signaling repression.
Xiong YX; Zhang XC; Zhu JH; Zhang YX; Pan YL; Wu Y; Zhao JP; Liu JJ; Lu YX; Liang HF; Zhang ZG; Zhang WG
Cell Death Differ; 2023 Jul; 30(7):1648-1665. PubMed ID: 37117273
[TBL] [Abstract][Full Text] [Related]
6. MCM2 promotes the stemness and sorafenib resistance of hepatocellular carcinoma cells via hippo signaling.
Zhou X; Luo J; Xie H; Wei Z; Li T; Liu J; Liao X; Zhu G; Peng T
Cell Death Discov; 2022 Oct; 8(1):418. PubMed ID: 36243809
[TBL] [Abstract][Full Text] [Related]
7. RHOA activity in expanding blastocysts is essential to regulate HIPPO-YAP signaling and to maintain the trophectoderm-specific gene expression program in a ROCK/actin filament-independent manner.
Marikawa Y; Alarcon VB
Mol Hum Reprod; 2019 Feb; 25(2):43-60. PubMed ID: 30395288
[TBL] [Abstract][Full Text] [Related]
8. A feedback loop of PPP and PI3K/AKT signal pathway drives regorafenib-resistance in HCC.
Yang H; Chen D; Wu Y; Zhou H; Diao W; Liu G; Li Q
Cancer Metab; 2023 Dec; 11(1):27. PubMed ID: 38111012
[TBL] [Abstract][Full Text] [Related]
9. TOP2A inhibition reverses drug resistance of hepatocellular carcinoma to regorafenib.
Wang Z; Zhu Q; Li X; Ren X; Li J; Zhang Y; Zeng S; Xu L; Dong X; Zhai B
Am J Cancer Res; 2022; 12(9):4343-4360. PubMed ID: 36225636
[TBL] [Abstract][Full Text] [Related]
10. FOXM1-CD44 Signaling Is Critical for the Acquisition of Regorafenib Resistance in Human Liver Cancer Cells.
Wuputra K; Hsiao PJ; Chang WT; Wu PH; Chen LA; Huang JW; Su WL; Yang YH; Wu DC; Yokoyama KK; Kuo KK
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887129
[TBL] [Abstract][Full Text] [Related]
11. RhoA enhances osteosarcoma resistance to MPPa-PDT via the Hippo/YAP signaling pathway.
Zhan F; He T; Chen Z; Zuo Q; Wang Y; Li Q; Zhong S; Ou Y
Cell Biosci; 2021 Oct; 11(1):179. PubMed ID: 34627383
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic restriction of Hippo signaling by MORC2 underlies stemness of hepatocellular carcinoma cells.
Wang T; Qin ZY; Wen LZ; Guo Y; Liu Q; Lei ZJ; Pan W; Liu KJ; Wang XW; Lai SJ; Sun WJ; Wei YL; Liu L; Guo L; Chen YQ; Wang J; Xiao HL; Bian XW; Chen DF; Wang B
Cell Death Differ; 2018 Dec; 25(12):2086-2100. PubMed ID: 29555977
[TBL] [Abstract][Full Text] [Related]
13. miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression.
Chen M; Wu L; Tu J; Zhao Z; Fan X; Mao J; Weng Q; Wu X; Huang L; Xu M; Ji J
EBioMedicine; 2018 Sep; 35():142-154. PubMed ID: 30111512
[TBL] [Abstract][Full Text] [Related]
14. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
[TBL] [Abstract][Full Text] [Related]
15. Evodiamine inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells via the Hippo-Yes-Associated Protein signaling pathway.
Zhao S; Xu K; Jiang R; Li DY; Guo XX; Zhou P; Tang JF; Li LS; Zeng D; Hu L; Ran JH; Li J; Chen DL
Life Sci; 2020 Jun; 251():117424. PubMed ID: 32057900
[TBL] [Abstract][Full Text] [Related]
16. Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway.
Wang J; Zhang N; Han Q; Lu W; Wang L; Yang D; Zheng M; Zhang Z; Liu H; Lee TH; Zhou XZ; Lu KP
Cancer Lett; 2019 Mar; 444():82-93. PubMed ID: 30583078
[TBL] [Abstract][Full Text] [Related]
17. Hyaluronan-CD44 interaction with leukemia-associated RhoGEF and epidermal growth factor receptor promotes Rho/Ras co-activation, phospholipase C epsilon-Ca2+ signaling, and cytoskeleton modification in head and neck squamous cell carcinoma cells.
Bourguignon LY; Gilad E; Brightman A; Diedrich F; Singleton P
J Biol Chem; 2006 May; 281(20):14026-40. PubMed ID: 16565089
[TBL] [Abstract][Full Text] [Related]
18. Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma.
Shi W; Zhang S; Ma D; Yan D; Zhang G; Cao Y; Wang Z; Wu J; Jiang C
Front Oncol; 2020; 10():694. PubMed ID: 32670862
[No Abstract] [Full Text] [Related]
19. CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ.
Hao X; Zhang Y; Shi X; Liu H; Zheng Z; Han G; Rong D; Zhang C; Tang W; Wang X
J Exp Clin Cancer Res; 2022 Sep; 41(1):281. PubMed ID: 36131287
[TBL] [Abstract][Full Text] [Related]
20. CD44 acts through RhoA to regulate YAP signaling.
Zhang Y; Xia H; Ge X; Chen Q; Yuan D; Chen Q; Leng W; Chen L; Tang Q; Bi F
Cell Signal; 2014 Nov; 26(11):2504-13. PubMed ID: 25101858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
